This guide explains what TA875 says in plain terms: the setting it recommends Wegovy in, the criteria it uses, and how NHS access under it differs from private access. It draws on the NICE guidance and the NHS, and it pairs with our guide on the equivalent Mounjaro appraisal, TA1026. It is general information, and your eligibility is something a clinician confirms.
What TA875 is
TA875 is a NICE technology appraisal, the type of guidance that decides whether a medicine is recommended for use in the NHS for a particular purpose, and on what terms 1. For semaglutide (Wegovy) in weight management, TA875 is the document that sets the NHS position 1.
A technology appraisal matters because NHS funding and access for a medicine generally follow what NICE recommends 1. So TA875 is effectively the rulebook for who can be offered Wegovy on the NHS for weight management, and in what context 1.
It is worth being clear from the start that this is about the NHS route 1. Private access through a registered pharmacy operates under the medicine's licence and the pharmacy's own assessment, which is a separate matter covered later in this guide 23.
Who TA875 recommends Wegovy for
TA875 recommends semaglutide for managing overweight and obesity for people who meet defined BMI thresholds together with weight-related health conditions, rather than for anyone wanting to lose weight 1. The criteria are specific, which is part of why NHS access is more limited than the general interest in the medicine 1.
It also recommends it as part of a structured weight management programme, used alongside a reduced-calorie diet and increased physical activity, reflecting that the medicine is meant to support lifestyle change rather than replace it 1. This mirrors how the medicine is licensed and how NICE frames weight management generally 1.
Because the exact thresholds and conditions are detailed and can be updated, the practical step is to have your eligibility checked against the current criteria by a clinician rather than to self-assess from a summary 1. This guide explains the shape of the criteria, not a definitive personal eligibility test 1.
The specialist-service setting
A defining feature of TA875 is that it recommends Wegovy within specialist weight management services, rather than as something routinely prescribed in general practice 1. This is a structured, supervised setting with the support such services provide 1.
That setting is one of the main reasons NHS access can feel limited: it depends on being referred to and seen by such a service, and on its capacity, in addition to meeting the clinical criteria 1. It is not simply a matter of asking a GP for a prescription 1.
The specialist setting also reflects that this is monitored treatment, with the assessment, support and review that weight management is meant to involve 1. NICE frames weight management around that kind of structured, multidisciplinary support more broadly 1.
Considering treatment for weight management? You can start an assessment with a Cloud Pharmacy clinician, who will review your medical history and confirm whether treatment is appropriate.
Use for a limited period
TA875 frames NHS use of semaglutide for weight management as being for a limited period rather than indefinitely 1. This reflects how it was studied and how the specialist service model is designed to work 1.
For patients, this means NHS treatment under TA875 is best understood as a defined course within a programme, not an open-ended prescription 1. What happens at the end of that period, and how to maintain progress, is part of the support the service provides 1.
It is another point of difference from how people sometimes imagine access works 1. The NHS route is a structured, time-limited, specialist programme, which is quite different from an assumption of ongoing supply on request 13.
How NHS access differs from private
The most common source of confusion is the gap between TA875's NHS criteria and what people see advertised privately 23. On the NHS, access follows TA875: defined criteria, a specialist service, and a limited period 1. That is deliberately more restrictive than general demand 1.
On a private basis, access is through a registered pharmacy under the medicine's licence and the pharmacy's own clinical assessment, which is a different framework from the NHS appraisal 23. Eligibility, setting and how long you stay on treatment can therefore look different from the NHS route 2.
Whichever route applies, the medicine itself and its licensed use are the same, and it should always be obtained through a registered pharmacy after a proper assessment 23. The NHS warns that some websites sell fake weight-loss medicines, so a registered route matters regardless of how you access it 2.
TA875 alongside the Mounjaro appraisal
TA875 sits alongside TA1026, the equivalent NICE appraisal for tirzepatide (Mounjaro) in weight management 1. Reading them together helps make sense of why NHS access for these medicines is structured and phased rather than immediate 1.
Both appraisals share the same broad logic: defined criteria, a structured and often specialist setting, and use alongside diet and activity, reflecting NICE's consistent approach to weight-management medicines 1. The specifics differ by medicine, which is why each has its own appraisal 1.
Our guide on NICE TA1026 for Mounjaro covers the tirzepatide side 1. Together, the two explain why the NHS picture is more limited and more structured than the level of public interest might suggest 13.
Reading the two together also helps explain why the NHS rollout of these medicines has been phased and sometimes slower than demand 13. When a treatment is recommended within specialist services and for specific groups, the NHS has to build the capacity to deliver it, which is part of why access has felt gradual even where a medicine is recommended 13.
Why appraisals like TA875 exist
It can be frustrating to find that a medicine you have read about is hard to get on the NHS, so it helps to understand what an appraisal like TA875 is actually for 1. NICE assesses whether a medicine should be recommended for NHS use, for whom, and on what terms, weighing the evidence so that NHS resources are directed where they do the most good 1.
That is why the recommendation is specific rather than open 1. Restricting NHS use to defined criteria, a specialist setting and a limited period is how the appraisal balances the benefit to those most likely to gain against the practicalities of funding and delivering treatment at scale 13. The structure is the point, not an accident 1.
For patients, the useful implication is that meeting the headline idea of the medicine is not the same as meeting the appraisal's criteria 1. The criteria are the gateway to NHS access, which is why having a clinician check them against your situation is the meaningful step rather than reading the general description 13.
It also explains why the picture can change over time 1. Appraisals can be updated as evidence develops and as the NHS plans how to roll treatment out, so the current version is always the one that matters, and an older summary may not reflect today's position 13.
What to do with this information
If you are wondering whether you could access Wegovy on the NHS, the practical step is to discuss it with a clinician who can check the current TA875 criteria against your circumstances and explain the referral route to a specialist service 13. That is far more useful than trying to judge eligibility from a summary 1.
If the NHS route is not open to you, or the wait is long, the private route through a registered pharmacy is a separate option under the medicine's licence and the pharmacy's assessment 23. Understanding that these are two different frameworks helps you weigh them sensibly rather than expecting one to behave like the other 2.
Whichever route you consider, the safety basics are the same: a proper assessment and a registered pharmacy, because the NHS warns that some websites sell fake weight-loss medicines 2. TA875 tells you how the NHS approaches the medicine; it does not change the rule that any supply should come through a legitimate, assessed route 23.
Reading TA875 alongside our other guides on access and on how the medicine works gives you the fullest picture 1. The headline to carry away is that NHS access is deliberately structured and criteria-based, that private access works differently, and that a clinician is the right person to tell you which applies to you 123.
It is also worth keeping a sense of perspective if you do not meet the NHS criteria right now 13. Criteria reflect where the evidence and resources are currently directed, not a judgement about you, and both the appraisals and the options can develop over time, so a conversation with your clinician about the route that fits you today is the most useful thing you can do with TA875 13. Knowing how the NHS approaches the medicine puts you in a far stronger position to have that conversation well 1.
Frequently asked questions
What is NICE TA875?
It is the NICE technology appraisal that sets out when semaglutide (Wegovy) is recommended for managing overweight and obesity on the NHS, and on what terms 1. NHS access and funding generally follow what NICE recommends 1.Who can get Wegovy on the NHS under TA875?
People who meet defined BMI thresholds together with weight-related health conditions, within a specialist weight management service and alongside diet and activity 1. The criteria are specific, so a clinician should check your eligibility against the current version 1.Why is NHS access to Wegovy so limited?
Because TA875 recommends it within specialist services, for people meeting specific criteria, and for a limited period, which depends on referral and service capacity as well as eligibility 1. It is not simply available on request from a GP 1.Is NHS use of Wegovy time-limited?
TA875 frames NHS use for weight management as being for a limited period within a programme, rather than indefinitely 1. What happens at the end of that period is part of the support the specialist service provides 1.How is private access different from TA875?
Private access is through a registered pharmacy under the medicine's licence and the pharmacy's own assessment, a different framework from the NHS appraisal 23. Eligibility, setting and treatment length can therefore look different from the NHS route 2.How does TA875 relate to TA1026?
TA875 covers semaglutide (Wegovy) and TA1026 covers tirzepatide (Mounjaro), and they share the same broad logic of defined criteria, a structured setting and use alongside lifestyle change 1. Each medicine has its own appraisal because the specifics differ 1.Your next step
NICE TA875 is the technology appraisal that sets the NHS position on semaglutide (Wegovy) for weight management. It recommends it within specialist weight management services, for people meeting defined BMI and weight-related health criteria, alongside diet and activity, and for a limited period rather than indefinitely. That is why NHS access is more structured and limited than the level of public interest might suggest.
TA875 governs the NHS route; private access through a registered pharmacy works under the medicine's licence and the pharmacy's own assessment, so eligibility, setting and treatment length can look different. Whichever applies, obtain the medicine only through a registered pharmacy after a proper assessment, and have a clinician check your eligibility against the current criteria rather than self-assessing. Read alongside our guide to TA1026 for Mounjaro, TA875 helps explain how the NHS approaches these medicines overall.
Disclaimer
This guide is for general information only and does not constitute medical advice, diagnosis or treatment. The information here describes general clinical context based on UK regulatory sources cited above; it is not a recommendation for any specific medicine or treatment, which can only be made by a prescriber following individual assessment.
If you are considering treatment, speak to your GP or pharmacist, or arrange a consultation with a Cloud Pharmacy clinician. Prescription-only medicines are issued only after clinical assessment and where appropriate.
If you experience side effects from any medicine, you can report them through the Yellow Card scheme at yellowcard.mhra.gov.uk.
References
- NICE TA875 1 Recommendations (semaglutide for managing overweight and obesity; BMI + weight-related comorbidity criteria; within specialist weight management services; alongside reduced-calorie diet and increased physical activity; limited period of use)
- Semaglutide (NHS context; registered pharmacy; some websites sell fake weight-loss medicines; assessment required)
- General NHS vs private access framing; eligibility-dependent NHS access (no specific price or guarantee asserted)
